MEI Pharma (NASDAQ:MEIP) has risen another 16.7% postmarket after citing updated clinical data from an early-stage trial.
The company announced data from an ongoing Phase
1b study of investigational ME-401 in patients with indolent B-cell
malignancies.
It will present the data at the company’s investor and analyst event, starting tomorrow at 8 a.m. ET.
The company will also review progress across the
pipeline of its four clinical-stage oncology candidates, with a focus on
voruciclib, a cyclin-dependent kinase inhibitor with potent CDK9
inhibition.
https://seekingalpha.com/news/3503880-mei-pharma-plus-16_7-percent-updated-early-stage-trial-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.